Why the study?
Dexmedetomidine may induce antiarrhythmic effects, especially against ventricular tachycardia, but the underlying electrophysiological mechanisms remain to be fully elucidated.
Does dexmedetomidine alter electrophysiological properties in human-induced pluripotent stem cell-derived cardiomyocytes?
Does dexmedetomidine alter electrophysiological properties in human-induced pluripotent stem cell-derived cardiomyocytes?
Dexmedetomidine exhibits antiarrhythmic effects on hiPSC-CMs by inhibiting sodium and calcium channels independently of adrenergic and imidazoline receptors.
Answers are grounded in this paper and cite their sources.
DMED effects in hiPSC-CMs require in vivo validation; leaves open clinical antiarrhythmic translation.
Background: Ventricular-like human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) exhibit the electrophysiological characteristics of spontaneous beating. Previous studies demonstrated that dexmedetomidine (DMED), a highly selective and widely used α2-adrenoceptor agonist for sedation, analgesia, and stress management, may induce antiarrhythmic effects, especially ventricular tachycardia. However, the underlying mechanisms of the DMED-mediated antiarrhythmic effects remain to be fully elucidated. Methods: A conventional patch-clamp recording method was used to investigate the direct effects of DMED on spontaneous action potentials, pacemaker currents (If), potassium (K+) channel currents (IK1 and IKr), sodium (Na+) channel currents (INa), and calcium (Ca2+) channel currents (ICa) in ventricular-like hiPSC-CMs. Results: DMED dose-dependently altered the frequency of ventricular-like spontaneous action potentials with a half-maximal inhibitory concentration (IC50) of 27.9 µM (n=6) and significantly prolonged the action potential duration at 90% repolarization (APD90). DMED also inhibited the amplitudes of the INa and ICa without affecting the activation and inactivation curves of these channels. DMED decreased the time constant of the Na+ and Ca2+ channel activation at potential –40 to –20 mv, and –20 mv. DMED increased the time constant of inactivation of the Na+ and Ca2+ channels. However, DMED did not affect the IK1, IKr, If, and their current-voltage relationship. The ability of DMED to decrease the spontaneous action potential frequency and the Na+ and Ca2+ channel amplitudes, were not blocked by yohimbine, idazoxan, or phentolamine. Conclusions: DMED could inhibit the frequency of spontaneous action potentials and decrease the INa and ICa of hiPSC-CMs via mechanisms that were independent of the α2-adrenoceptor, the imidazoline receptor, and the α1-adrenoceptor. These inhibitory effects on hiPSC-CMs may contribute to the antiarrhythmic effects of DMED.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: